SALT
LAKE CITY, Sept. 4, 2024 /PRNewswire/ -- Sera
Prognostics Inc., The Pregnancy Company®
(NASDAQ: SERA), focused on improving maternal and neonatal health
by providing innovative pregnancy biomarker information to doctors
and patients, today announced that the company will present at the
H.C. Wainwright Global Investment Conference on Wednesday, September 11, 2024 at 10:00 a.m. ET. Zhenya Lindgardt, President
and CEO, will provide a company update and discuss Sera's latest
achievements.
A live webcast of the company's presentation as well as a
webcast replay will be available online from the Investors page of
the Company's website at www.seraprognostics.com.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company
dedicated to improving the lives of women and babies through
precision pregnancy care. Sera's mission is to provide early,
pivotal pregnancy information to improve the health of mothers and
newborns, resulting in reductions in the costs of healthcare
delivery. Sera has a robust pipeline of innovative diagnostic tests
focused on the early prediction of preterm birth risk and other
complications of pregnancy. Sera's precision medicine
PreTRM® Test reports to a physician the individualized
risk of spontaneous premature delivery in a pregnancy, enabling
earlier proactive interventions in women with higher risk. Sera
Prognostics is headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation
and is the leading cause of illness and death in newborns. The 2023
March of Dimes Report Card shows that, for the last five
consecutive years, more than one in ten infants is born prematurely
in the United States. Prematurity
is associated with a significantly increased risk of major
long-term medical complications, including learning disabilities,
cerebral palsy, chronic respiratory illness, intellectual
disability, seizures, and vision and hearing loss, and can generate
significant costs throughout the lives of affected children. The
annual health care costs to manage short- and long-term
complications of prematurity in the United States were
estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated,
commercially available blood-based biomarker test that provides an
early, accurate and individualized risk prediction for spontaneous
preterm birth in asymptomatic singleton pregnancies. The
PreTRM® Test measures and analyzes proteins in the blood
that are highly predictive of preterm birth. The PreTRM®
Test permits physicians to identify, during the weeks 18 through 20
of pregnancy, which women are at increased risk for preterm birth
and its complications, enabling more informed, personalized
clinical decisions based on each woman's individual risk. The
PreTRM® Test is ordered by a medical professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy
Company, and PreTRM are trademarks or registered trademarks of Sera
Prognostics, Inc. in the United States and/or other
countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the date, time and content
of the Company's presentation at the H.C. Wainwright
26th Annual Global Investment Conference; and the
company's strategic directives under the caption "About Sera
Prognostics, Inc." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: net losses, cash
generation, and the potential need to raise more capital; revenues
from the PreTRM Test representing substantially all Company
revenues to date; the need for broad scientific and market
acceptance of the PreTRM Test; a concentrated number of material
customers; our ability to introduce new products; potential
competition; our proprietary biobank; critical suppliers; the
COVID-19 pandemic and its potential lingering impact on our
operations, as well as the business or operations of third parties
with whom we conduct business; estimates of total addressable
market opportunity and forecasts of market growth; potential
third-party payer coverage and reimbursement; new reimbursement
methodologies applicable to the PreTRM Test, including new CPT
codes and payment rates for those codes; changes in FDA regulation
of laboratory-developed tests; the intellectual property rights
protecting our tests and market position; and other factors
discussed under the heading "Risk Factors" contained in our Final
Prospectus on Form S-1, which was filed with the Securities and
Exchange Commission on July 14, 2021,
as well as any updates to those risk factors filed from time to
time in our Quarterly Reports on Form 10-Q, Annual Reports on Form
10-K, or Current Reports on Form 8-K. All information in this press
release is as of the date of the release, and the Company
undertakes no duty to update this information unless required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-to-present-at-hc-wainwright-26th-annual-global-investment-conference-302238600.html
SOURCE Sera Prognostics, Inc.